Iktos is a pioneering company specializing in artificial intelligence (AI) and robotics to revolutionize drug discovery. By integrating generative AI with automated synthesis and testing, Iktos accelerates the development of new treatments, aiming to improve patient care through fully autonomous laboratories. Their innovative approach shortens the drug discovery phase to under two years, significantly enhancing efficiency in pharmaceutical research and development.
Key Features and Functionality:
- Generative AI Platform (Makya): Makya is Iktos's generative AI software-as-a-service (SaaS) platform designed for de novo drug design. It creates diverse, novel, and medicinal chemistry-like molecules, ensuring each is synthetically accessible and optimized for success.
- Retrosynthesis AI (Spaya): Spaya is an AI-driven retrosynthesis platform that identifies the most feasible synthetic routes, converting target compounds into commercially available starting materials. This data-driven approach optimizes the synthesis process, making it compatible with robotic systems.
- Autonomous Laboratory (Iktos Robotics Chemistry): Iktos's autonomous lab manages the complete synthetic process, from workflow management and ordering raw materials to executing chemical synthesis. This AI-driven Design-Make-Test-Analyze (DMTA) process significantly reduces the time to identify viable drug candidates.
- In-Cellulo Screening (Iktos Robotics Biology): Utilizing multidimensional biological data generated from their imaging platform, Iktos identifies small-molecule modulators of protein activity, protein-protein, and RNA-protein interactions in biologically relevant environments. This enables continuous optimization of molecular properties, even for challenging targets.
Primary Value and Problem Solved:
Iktos addresses the inefficiencies in traditional drug discovery by integrating AI and robotics, thereby accelerating the development of new therapeutics. Their platform enables rapid identification and optimization of drug candidates, reducing the time and cost associated with bringing new drugs to market. By automating the DMTA cycle and ensuring synthetic accessibility, Iktos enhances productivity in pharmaceutical R&D, ultimately contributing to improved patient outcomes.
